Yield10 Bioscience - YTEN Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" YTEN shares.
View YTEN analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12 month price objectives for Yield10 Bioscience's stock. Their YTEN share price forecasts range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 334.8% from the stock's current price.
View analysts price targets for YTEN or view top-rated stocks among Wall Street analysts.

Yield10 Bioscience's stock was trading at $1.6695 at the start of the year. Since then, YTEN stock has increased by 65.3% and is now trading at $2.76.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our YTEN earnings forecast.

Yield10 Bioscience, Inc. (NASDAQ:YTEN) posted its quarterly earnings data on Tuesday, November, 9th. The specialty chemicals company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.16. The specialty chemicals company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.22 million. Yield10 Bioscience had a negative net margin of 3,014.67% and a negative trailing twelve-month return on equity of 154.59%. During the same quarter in the previous year, the business posted ($0.87) EPS.

Shares of Yield10 Bioscience reverse split on Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Yield10 Bioscience investors own include KushCo (KSHB), OPKO Health (OPK), T2 Biosystems (TTOO), FuelCell Energy (FCEL), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Rigel Pharmaceuticals (RIGL), Advanced Micro Devices (AMD).

Yield10 Bioscience trades on the NASDAQ under the ticker symbol "YTEN."

Yield10 Bioscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cannell & Co. (5.22%). Insiders that own company stock include Anthony J Sinskey, Charles B Haaser and Jack W Schuler.
View institutional ownership trends.

Shares of YTEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of YTEN stock can currently be purchased for approximately $2.76.

Yield10 Bioscience (NASDAQ:YTEN) has a market capitalization of $13.99 million and generates $450,000.00 in revenue each year. The specialty chemicals company earns $-13,570,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.

Yield10 Bioscience's mailing address is 19 PRESIDENTIAL WAY, WOBURN MA, 01801. The official website for the company is www.yield10bio.com. The specialty chemicals company can be reached via phone at (617) 583-1700, via email at brets@coreir.com, or via fax at 617-583-1768.